Cambrex Recognized in 2021 CMO Leadership Awards


East Rutherford, NJ – February 19, 2021 – Cambrex today announced that it had been recognized across six categories in the annual CMO (Contract Manufacturing Organization) Leadership Awards.

Cambrex has now received CMO awards for seven consecutive years, and this year, has been recognized in the following categories: Capabilities (Overall, Small Pharma), Compatibility (Overall, Small Pharma), Expertise (Overall, Small Pharma), Quality (Overall, Small Pharma), Reliability (Small Pharma), and Service (Overall, Small Pharma).

“Once again, Cambrex is honored to be recognized by our customers and industry peers as a leading supplier to the pharmaceutical industry”, commented Tom Loewald, Chief Executive Officer at Cambrex. He added, “Demand for small molecule manufacturing constantly grows and evolves, and we are committed to investing in the capacity, capabilities and expertise to further strengthen our position as a market-leading CDMO delivering customized, customer-centric solutions.”

Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma, added, “Congratulations to all the 2021 CMO Leadership Award winners; you keep the biopharma industry moving forward. An award in any category – capabilities, compatibility, expertise, quality, reliability and service – acknowledges your advanced leadership and effective execution and that rare flexibility to serve all customers through even the most difficult of times.”

In 2019, Cambrex was acquired by funds advised by Permira, a global investment firm, to continue to build upon Cambrex’s market leading position in API development and manufacturing and support the growth of its end-to-end integrated service offerings across the pharmaceutical value chain.

Established in 2011, the CMO Leadership Awards recognize top outsourcing partners, determined by feedback from sponsor companies who outsource manufacturing. The awards are presented by Outsourced Pharma, Life Science Leader magazine and Industry Standard Research.

About Cambrex
Cambrex is the leading small molecule company that provides drug substance, drug product, and analytical services across the entire drug lifecycle. The company provides customers with an end-to-end partnership for the research, development, and manufacture of small molecule therapeutics. With over 40 years’ experience and a growing team of over 2,100 experts servicing global clients from sites in North America and Europe, Cambrex is a trusted partner in branded and generic markets for API and dosage form development and manufacturing.

Cambrex offers a range of specialist drug substance technologies and capabilities, including biocatalysis, continuous flow, controlled substances, solid state science, material characterization, and highly potent APIs. In addition, Cambrex can support conventional dosage forms, including oral solids, semi-solids, and liquids, and has the expertise to manufacture specialist dosage forms such as modified-release, fixed-dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile and non-sterile ointments.